AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Neurturin (NTN) is a neurotrophic factor with known potential to protect and restore the function of dopaminergic substantia nigra neurons whose degeneration has been most closely linked to the major motor deficits in Parkinson's disease (PD). CERE-120, an adeno-associated virus serotype 2 (AAV2)-based gene delivery vector encoding human NTN, is being developed as a potential therapeutic for PD. In a series of preclinical studies reported herein, CERE-120 delivery to the striatum produced a dose-related neuroprotection of nigrostriatal neurons in the rat 6-hydroxydopamine (6-OHDA) lesion model. Long-lasting efficacy of CERE-120 was evidenced by substantia nigra cell protection, preserved fiber innervation of the striatum, and behavioral recovery for at least 6 months. In addition, striatal infusion of CERE-120 was found to have a safety and tolerability profile devoid of side effects or toxicological responses, for at least 12 months post-treatment, even at dose multiples 125 times that of the lowest efficacious dose tested. These results support the ongoing CERE-120 clinical program in PD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Neurturin, a relative of glial-cell-line-derived neurotrophic factor
Kotzbauer, P. T., Lampe, P. A., Heuckeroth, R. O., Golden, J. P., Creedon, D. J., Johnson Jr, E. M., & Milbrandt, J. (1996) · Nature · doi:10.1038/384467a0 · Cited by 710
Winkler, C., Sauer, H., Lee, C. S., & Björklund, A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-22-07206.1996 · Cited by 258
Immune responses to AAV in a phase I study for Canavan disease
McPhee, S. W. J., Janson, C. G., Li, C., Samulski, R. J., Camp, A. S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.885 · Cited by 241
Fjord-Larsen, L., Johansen, J. L., Kusk, P., Tornøe, J., Grønborg, M., Rosenblad, C., & Wahlberg, L. U. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.03.006 · Cited by 93
Research works printed but not linked: 31
- Akerud, 1999, Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons, J. Neurochem., 73, 70, 10.1046/j.1471-4159.1999.0730070.x · DOI · Paper page
- Crystal, 2004, Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis, Human Gene Therapy, 11, 1131
- Dass, B., et al., submitted for publication. Dose-related transgene expression and bioactivity in the monkey nigrostriatal system following intrastriatal delivery of AAV2–Neurturin (CERE-120). Journal of Comparative Neurology.
- During, 2001, Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation, Hum Gene Ther., 12, 1589
- Eriksdotter Jonhagen, 1998, Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease, Dement. Geriatr Cogn. Disord., 9, 246, 10.1159/000017069 · DOI · Paper page
- Gasmi, 2007, Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease, Mol. Ther., 15, 62, 10.1038/sj.mt.6300010 · DOI · Paper page
- Georgievska, 2002, errant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer, Exp. Neurol., 177, 461, 10.1006/exnr.2002.8006 · DOI · Paper page
- Georgievska, 2004, Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system, J. Neurosci., 24, 6437, 10.1523/JNEUROSCI.1122-04.2004 · DOI · Paper page
- Herzog, C.D., et al., in press. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Movement Disorders (April 18, 2007, Epub ahead of print). · DOI · Paper page
- Hoane, 1999, Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor, Exp. Neurol., 160, 235, 10.1006/exnr.1999.7175 · DOI
- Horger, 1998, Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons, J. Neurosci., 18, 4929, 10.1523/JNEUROSCI.18-13-04929.1998 · DOI · Paper page
- Kirik, 2000, Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system, J. Neurosci., 20, 4686, 10.1523/JNEUROSCI.20-12-04686.2000 · DOI · Paper page
- Kordower, 1999, Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease, Ann. Neurol., 46, 419, 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q · doi:10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q
- Kordower, 2006, Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys, Ann. Neurol., 60, 706, 10.1002/ana.21032 · DOI · Paper page
- Lang, 2006, Randomized controlled trial of intraputamenal glial cell line- derived neurotrophic factor infusion in Parkinson disease, Ann. Neurol., 59, 459, 10.1002/ana.20737 · DOI · Paper page
- Love, 2005, Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain, Nat. Med., 11, 703, 10.1038/nm0705-703 · DOI · Paper page
- Mandel, 1997, Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats, Proc. Natl. Acad Sci. U. S. A., 94, 14083, 10.1073/pnas.94.25.14083 · DOI · Paper page
- Mandel, 1999, Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson’s disease, Exp. Neurol., 160, 205, 10.1006/exnr.1999.7203 · DOI
- McBride, 2002, Neuroprotection for Parkinson’s disease using viral vector-mediated delivery of GDNF, Prog. Brain Res., 138, 421, 10.1016/S0079-6123(02)38091-9 · DOI
- McCown, 2005, Adeno-associated virus (AAV) vectors in the CNS, Curr Gene Ther., 5, 333, 10.2174/1566523054064995 · DOI · Paper page
- Nutt, 2003, Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD, Neurology, 60, 69, 10.1212/WNL.60.1.69 · DOI · Paper page
- Oiwa, 2002, Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease, Brain Res., 947, 271, 10.1016/S0006-8993(02)02934-7 · DOI
- Rosenblad, 1998, Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson’s disease, Neuroscience, 82, 129, 10.1016/S0306-4522(97)00269-8 · DOI
- Rosenblad, 1999, Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle, Eur. J. Neurosci., 11, 1554, 10.1046/j.1460-9568.1999.00566.x · DOI · Paper page
- Rosenblad, 2003, Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system, Eur. J. Neurosci., 17, 260, 10.1046/j.1460-9568.2003.02456.x · DOI · Paper page
- Salvatore, 2006, Point source concentration of GDNF may explain failure of Phase II clinical trial, Exp. Neurol., 202, 497, 10.1016/j.expneurol.2006.07.015 · DOI · Paper page
- Sherer, 2006, Crossroads in GDNF therapy for Parkinson’s disease, Mov. Disord., 21, 136, 10.1002/mds.20861 · DOI · Paper page
- Slevin, 2005, Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor, J. Neurosurg., 102, 216, 10.3171/jns.2005.102.2.0216 · DOI · Paper page
- Tseng, 1998, Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy, NeuroReport, 9, 1817, 10.1097/00001756-199806010-00027 · DOI · Paper page
- Ungerstedt, 1970, Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system, Brain Res., 24, 485, 10.1016/0006-8993(70)90187-3 · DOI · Paper page
- Wang, 2002, Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson’s disease, Gene Ther., 9, 381, 10.1038/sj.gt.3301682 · DOI
Cited by
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Missing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Self-citationMarks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Self-citationMarks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Self-citationTet-On Systems For Doxycycline-inducible Gene Expression
T. Das, A., Tenenbaum, L., & Berkhout, B. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160524144041 · Cited by 434
“viral genomes/mm 3 , the dose approved for the AAVneurturin clinical trial [34].”
BackgroundTherapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Viral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
“The prime example is neurturin (NRTN), a natural analog of glia-derived neurotropic factor (GDNF), which has been shown to protect dopaminergic neurons in pre-clinical studies (Kordower et al., 2006; Gasmi et al., 2007a,b).”
BackgroundMead, B. P., Kim, N., Miller, G. W., Hodges, D., Mastorakos, P., Klibanov, A. L., Mandell, J. W., Hirsh, J., Suk, J. S., Hanes, J., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00616 · Cited by 151
Bartus, R. T., & Johnson, E. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.03.027 · Cited by 97
Self-citationChu, Y., Bartus, R. T., Manfredsson, F. P., Olanow, C. W., & Kordower, J. H. (2020) · Brain · doi:10.1093/brain/awaa020 · Cited by 88
“In rodents and non-human primates, CERE120 has been shown to protect the integrity of nigrostriatal neurons from neurotoxic insult, and to increase dopamine expression in aged monkeys (Kordower et al., 2006; Gasmi et al., 2007; Herzog et al., 2007, 2013).”
BackgroundSelf-citationClinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
Herzog, C. D., Dass, B., Gasmi, M., Bakay, R., Stansell, J. E., Tuszynski, M., Bankiewicz, K., Chen, E.-Y., Chu, Y., Bishop, K., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.170 · Cited by 72
Self-citationTrophic factors therapy in Parkinson's disease
Ramaswamy, S., Soderstrom, K. E., & Kordower, J. H. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17514-3 · Cited by 72
Self-citationAdeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
Chtarto, A., Humbert-Claude, M., Bockstael, O., Das, A. T., Boutry, S., Breger, L. S., Klaver, B., Melas, C., Barroso-Chinea, P., Gonzalez-Hernandez, T., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.27 · Cited by 43
Fajardo-Serrano, A., Rico, A. J., Roda, E., Honrubia, A., Arrieta, S., Ariznabarreta, G., Chocarro, J., Lorenzo-Ramos, E., Pejenaute, A., Vázquez, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126389 · Cited by 32
Herzog, C. D., Bishop, K. M., Brown, L., Wilson, A., Kordower, J. H., & Bartus, R. T. (2011) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0037-z · Cited by 29
“virtually identical to that seen in young adult Sprague-Dawley rats following administration of the same dose of AAV2-NRTN reported previously from 3 to 12 months [ 40 ] (see Fig. 2a) and at 18–20 months following delivery (Experiment 2 of the present manuscript).”
BackgroundMethodResultInfluentialSelf-citation
Metadata
- Authors
- Gasmi, M., Brandon, E. P., Herzog, C. D., Wilson, A., Bishop, K. M., Hofer, E. K., Cunningham, J. J., Printz, M. A., Kordower, J. H., & Bartus, R. T.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 27
- Issue
- 1
- Pages
- 67-76
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2086480069
- Cited by
- 141
- References
- 6
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.